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Molecular communication (MC) is an emerging nanoscale communication paradigm, 
biologically inspired by the cellular communications via biochemical molecules in the living 
organisms. The MC paradigm is highly suitable for modelling and abstraction of the 
underlying complex processes in the drug delivery systems (DDSs) over wide spatiotemporal 
scales. Targeted and implantable DDSs are advanced and engineered technologies for 
effective delivery of anticancer drugs to the cancerous tumors without affecting other healthy 
parts in the body. This approach offers an efficient alternative or adjunctive therapy to other 
treatment techniques, such as conventional chemotherapy, thermal ablation, and surgical 
resection. In-Silico (mathematical and stochastic) models are key tools to understand and 
quantify the various parameters and processes in the DDSs, including drug transport, release 
processes, reaction, and other physicochemical interaction processes in the biological 
microenvironments inside the body. These models play an essential role in the design and 
development of the DDSs which in order can reduce the animal experiments and can save 
time and reduce cost.   
The focus of my Ph.D. research is to develop novel mathematical and stochastic simulation 
models using MC paradigm for localized targeted and implantable DDSs over nano- and 
micrometer scales in complex biological microenvironments. Using the MC paradigm, the 
drug delivery process is abstracted as a communication mechanism where the drug source 
acts as a transmitter while the target site (e.g., cancer cell) acts as a receiver and the biological 
environment through which the molecules get transported acts as a propagation channel. The 
anticancer drug molecules represent the information carriers that contain the 
physicochemical properties of the drug. We use system analysis approach using the channel 
impulse response (CIR) coupled with the signal processing technique (convolution) for 
modelling the targeted and implantable DDSs in tumor microenvironments (TME). This 
approach provides more general and flexible models compared to other modelling 
approaches.  
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The thesis made original contributions in the following four major aspects: 
(1) Generalized mathematical and stochastic simulation models are developed for diffusion-
based molecular communications (MC) in complex fluidic microenvironments that include 
multilayered physical structures, ligand-receptor reaction, anisotropic diffusion, and the 
effect of reactive obstacles. These generalized models are developed for modelling and 
design of both the targeted drug delivery systems (TDDS) as well as the molecular 
communication systems between bio-nanomachines or cells in such complex environments 
over microscopic scale. (2) The proposed multilayer MC models have been extended for 
modelling the intravascular TDDS including anticancer drug release from the nanocarriers 
(NCs) and drug transport across the endothelial barrier of the tumor vasculature in tumor 
microenvironments. (3) Novel mathematical and stochastic simulation models are developed 
for modelling the implantable drug delivery system (IDDS) in tumor by predicting and 
characterizing the release process and drug distribution in the surrounding tumor tissue. (4) 
Pharmacokinetic /Pharmacodynamics models are developed for modelling the combination 
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CIR Channel Impulse Response  
CT Computed Tomography 
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